Strategies to detect adverse effects of antiepileptic drugs in clinical practice

Epilepsy and Behavior

Volumn 13, Issue 1, 2008, Pages 178-183

  Carreno M ^a   Gil Nagel, A ^b   Sanchez J C ^c   Elices, E ^d   Serratosa, J M ^e   Salas Puig, J ^f   Villanueva, V ^g   Porcel, J ^h  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL RUBER INTERNACIONAL   (Spain)

^c HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^e Jimenez Diaz Foundation   (Spain)

^f Central University Hospital   (Spain)

^g HOSPITAL UNIVERSITARIO LA FE   (Spain)

^h Biometrica   (Spain)

Author keywords

Adverse effects; Checklist; Epilepsy; Spontaneous reporting; Treatment

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VALPROMIDE; VIGABATRIN;

ABSENCE; ACADEMIC FAILURE; ADULT; AGED; AGGRESSIVENESS; AGITATION; ANOREXIA; ARTICLE; ATONIC SEIZURE; BEHAVIOR DISORDER; BLURRED VISION; CENTRAL NERVOUS SYSTEM DISEASE; CHECKLIST; CLINICAL DECISION MAKING; CLINICAL PRACTICE; COGNITIVE DEFECT; COMBINATION CHEMOTHERAPY; COMPLEX PARTIAL SEIZURE; CONCENTRATION LOSS; DEFECATION DISORDER; DEPRESSION; DIARRHEA; DIPLOPIA; DIZZINESS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EPILEPSY; FALLING; FATIGUE; FEMALE; FOCAL EPILEPSY; GASTROINTESTINAL SYMPTOM; GINGIVA DISEASE; GRAND MAL SEIZURE; HAIR LOSS; HIRSUTISM; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; LANGUAGE DISABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MONOTHERAPY; MOOD DISORDER; MOTOR DYSFUNCTION; MYOCLONUS SEIZURE; NAUSEA; PATIENT CARE; PATIENT SELECTION; POLYPHARMACY; SELF REPORT; SIDE EFFECT; SIMPLE PARTIAL SEIZURE; SKIN DISEASE; SLEEP DISORDER; SOMNOLENCE; SPEECH DISORDER; TONIC CLONIC SEIZURE; TONIC SEIZURE; TREMOR; VERTIGO; VISUAL DISORDER; WALKING DIFFICULTY; WEIGHT GAIN; WEIGHT REDUCTION;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION REPORTING SYSTEMS; AGED; ANTICONVULSANTS; CROSS-SECTIONAL STUDIES; EPILEPSY; FEMALE; HUMANS; MALE; MIDDLE AGED;

EID: 46549086280     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2008.02.006     Document Type: Article

References (19)

1. Deckers C.L., Hekster Y.A., Keyser A., Lammers M.W., Meinardi H., and Renier W.O. Adverse effects in epilepsy therapy: wait and see or go for it?. Acta Neurol Scand 95 (1997) 248-252
2. Trenite D.G., Rentmeester T.W., Scholtes F.B., Gilissen K.G., Arends L.R., and Schlosser A. Peri-marketing surveillance of lamotrigine in The Netherlands: doctors' and patients' viewpoints. Pharm World Sci 23 (2001) 1-5
3. Carpay J.A., Aldenkamp A.P., and van Donselaar C.A. Complaints associated with the use of antiepileptic drugs: results from a community-based study. Seizure 14 (2005) 198-206
4. Uijl S.G., Uiterwaal C.S.M.P., Aldenkamp A.P., et al. A cross-sectional study of subjective complaints in patients with epilepsy who seem to be well-controlled with anti-epileptic drugs. Seizure 15 (2006) 242-248
5. Collaborative Group for Epidemiology of Epilepsy. Adverse reactions to anti-epileptic drugs: a multicenter survey of clinical practice. Epilepsy 1986;27:323-30.
6. Genton P., and Biraben A. [Use of topiramate in clinical practice: Part 2. Multicentric retrospective evaluation of its safety]. Rev Neurol (Paris) 156 (2000) 1120-1125
7. Gilliam F.G., Fessler A.J., Baker G., Vahle V., Carter J., and Attarian H. Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial. Neurology 62 (2006) 23-27
8. Greenwood R.S. Adverse effects of antiepileptic drugs. Epilepsy 41 (2000) S42-S52
9. Gilliam F. Optimizing health outcomes in active epilepsy. Neurology 58 (2002) S9-S20
10. Langfitt J., and Meador K. Want to improve epilepsy care? Ask the patient. Neurology 62 (2004) 6-7
11. Guevara J., Carmona G., Ortega M.P., and Iglesias A.A. Preliminary study on the efficacy and tolerability of newer anticonvulsants in a population of epileptic patients. Med Princ Pract 14 (2005) 31-34
12. Cramer J.A., Fisher R., Ben-Manachem E., French J., and Mattson R.H. New antiepileptic drugs: comparison of key clinical trials. Epilepsia 40 (1999) 590-600
13. Morris III G.L. Efficacy and tolerability of gabapentin in clinical practice. Clin Ther 17 (1995) 891-900
14. Herranz J.L. Topiramate: a broad spectrum antiepileptic administered to 224 patients with refractory epilepsies. Rev Neurol 31 (2000) 822-828
15. Reith D., Burke C., Appelton D.B., Wallace G., and Pelekanos J. Tolerability of topiramate in children and adolescents. J Paediatr Child Health 39 (2003) 416-419
16. Huber B., and Tomka-Hoffmeister M. Limited efficacy of gabapentin in severe therapy-resistant epilepsies of learning-disabled patients. Seizure 12 (2003) 602-603
17. Huber B., Bommel W., Hauser I., et al. Efficacy and tolerability of levetiracetam in patients with therapy-resistant epilepsy and learning disabilities. Seizure 13 (2004) 168-175
18. Hendriks M.P.H., Aldenkamp A.P., van der Vlugt H., Alpherts W.C.J., and Vermeulen J. Memory complaints in medically refractory epilepsy: relationship to epilepsy-related factors. Epilepsy Behav 3 (2002) 165-172
19. Gilliam F.G., Barry J.J., Hermann B.P., Meador K.J., Vahle V., and Kanner A.M. Rapid detection of major depression in epilepsy: a multicentre study. Lancet Neurol 5 (2006) 399-405